{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:16:00Z","timestamp":1761178560309,"version":"build-2065373602"},"reference-count":55,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.canrad.2019.06.005","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T08:00:58Z","timestamp":1565164858000},"page":"732-736","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pr\u00e9servation par chimioradioth\u00e9rapie des cancers de vessie"],"prefix":"10.1016","volume":"23","author":[{"given":"C.","family":"Durdux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Fabiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"M\u00e9jean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2019.06.005_bib0280","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.purol.2018.07.283","article-title":"Recommandations fran\u00e7aises du comit\u00e9 de canc\u00e9rologie de l\u2019Afu. Actualisation 2018-2020\u00a0: tumeurs de la vessie","volume":"28","author":"Roupr\u00eat","year":"2018","journal-title":"Prog Urol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0285","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bju.12121","article-title":"Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes","volume":"113","author":"Lee","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.canrad.2019.06.005_bib0290","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ucl.2017.12.008","article-title":"Quality of life after radical cystectomy","volume":"45","author":"Tyson","year":"2018","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.canrad.2019.06.005_bib0295","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054\u00a0patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0300","first-page":"553","article-title":"Study of survival after cystectomy for bladder cancer. Report of 504\u00a0cases","volume":"10","author":"Lebret","year":"2000","journal-title":"Prog Urol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0305","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1464-410X.2008.07636.x","article-title":"Cystectomy in the elderly: does the survival benefit in younger patients translate to the octogenarians?","volume":"102","author":"Chamie","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.canrad.2019.06.005_bib0310","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/cncr.21354","article-title":"Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study","volume":"104","author":"Prout","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2019.06.005_bib0315","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1002\/1097-0142(19920601)69:11<2771::AID-CNCR2820691124>3.0.CO;2-D","article-title":"The management of invasive transitional cell carcinoma of the bladder. Results of definitive and preoperative radiation therapy in 390\u00a0patients treated at the Prince of Wales Hospital, Sydney, Australia","volume":"69","author":"Mameghan","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2019.06.005_bib0320","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/S0022-5347(17)39122-X","article-title":"Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis","volume":"142","author":"Gospodarowicz","year":"1989","journal-title":"J Urol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0325","first-page":"340","article-title":"La radioth\u00e9rapie dans les cancers de vessie","volume":"2","author":"Ponvert","year":"2002","journal-title":"Oncologie"},{"key":"10.1016\/j.canrad.2019.06.005_bib0330","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/0090-4295(82)90115-7","article-title":"Invasive bladder carcinoma managed by irradiation and surgery","volume":"20","author":"DeWeerd","year":"1982","journal-title":"Urology"},{"key":"10.1016\/j.canrad.2019.06.005_bib0335","first-page":"453","article-title":"Carcinoma of the urinary bladder category T3\u00a0NX M0\u00a0treated by preoperative irradiation followed by simple cystectomy","volume":"260","author":"van der Werf-Messing","year":"1988","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.canrad.2019.06.005_bib0340","first-page":"S88","article-title":"Cisplatin and derivatives with radiation therapy: for what clinical use?","volume":"8","author":"Durdux","year":"2004","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2019.06.005_bib0345","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/0360-3016(93)90306-G","article-title":"Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12","volume":"25","author":"Tester","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2019.06.005_bib0350","first-page":"75","article-title":"The NCI-Canada trial of concurrent cisplatin and radiotherapy for muscle invasive bladder cancer","volume":"353","author":"Coppin","year":"1990","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.canrad.2019.06.005_bib0355","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1200\/JCO.1993.11.11.2150","article-title":"Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study","volume":"11","author":"Housset","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0360","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0360-3016(90)90498-9","article-title":"Combined 5-fluorouracil and irradiation for transitional cell carcinoma of the urinary bladder","volume":"19","author":"Russell","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2019.06.005_bib0365","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/0360-3016(90)90449-T","article-title":"Treatment of advanced transitional cell carcinoma of the bladder with irradiation and concomitant 5-fluorouracil infusion","volume":"18","author":"Rotman","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2019.06.005_bib0370","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0022-5347(01)65563-0","article-title":"Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy","volume":"156","author":"Chauvet","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0375","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2002.11.027","article-title":"Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results","volume":"20","author":"R\u00f6del","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0380","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1038\/sj.bjc.6601852","article-title":"Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer","volume":"90","author":"Hussain","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.canrad.2019.06.005_bib0385","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.radonc.2005.01.007","article-title":"Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer","volume":"75","author":"Kragelj","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0390","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.radonc.2006.09.001","article-title":"Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans-Tasman Radiation Oncology Group","volume":"81","author":"Gogna","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0395","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijrobp.2009.10.038","article-title":"Study group on genito-urinary tumors quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015)","volume":"79","author":"Lagrange","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2019.06.005_bib0400","first-page":"985","article-title":"15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment","volume":"31","author":"Krause","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.canrad.2019.06.005_bib0405","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.urology.2012.07.045","article-title":"Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent, radio-chemotherapy","volume":"80","author":"Zapatero","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.canrad.2019.06.005_bib0410","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1016\/j.ijrobp.2011.05.051","article-title":"Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience","volume":"82","author":"Tunio","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2019.06.005_bib0415","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0420","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3233\/BLC-160072","article-title":"Patterns of bladder preservation therapy utilization for muscle-invasive bladder cancer","volume":"2","author":"Rose","year":"2016","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.canrad.2019.06.005_bib0425","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving trimodality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0430","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1159\/000477912","article-title":"The efficacy of trimodal chemoradiotherapy with cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer","volume":"99","author":"Nagao","year":"2017","journal-title":"Urol Int"},{"key":"10.1016\/j.canrad.2019.06.005_bib0435","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1097\/01.ju.0000140456.42509.b6","article-title":"Effective bladder-sparing therapy with intra-arterial cisplatin and radiotherapy for localized bladder cancer","volume":"172","author":"Eapen","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0440","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s11604-007-0211-x","article-title":"Effective bladder preservation strategy with low-dose radiation therapy and concurrent intraarterial chemotherapy for muscle-invasive bladder cancer","volume":"26","author":"Ikushima","year":"2008","journal-title":"Radiat Med"},{"key":"10.1016\/j.canrad.2019.06.005_bib0445","first-page":"A2120","article-title":"Quality of life after combined radiation and chemotherapy with organ sparing for invasive bladder cancer","author":"Housset","year":"1998","journal-title":"Proc ASTRO"},{"key":"10.1016\/j.canrad.2019.06.005_bib0450","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.eururo.2009.12.002","article-title":"Differential complication rates following radical cystectomy in the irradiated and non-irradiated pelvis","volume":"57","author":"Ramani","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0455","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/01.coc.0000054890.69365.3E","article-title":"Tolerance of radiotherapy and chemotherapy in elderly patients with bladder cancer","volume":"27","author":"Goffin","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0460","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/01.ju.0000093721.23249.c3","article-title":"Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors","volume":"170","author":"Zietman","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0465","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bju.13900","article-title":"Clinical and patient-reported outcomes of SPARE\u00a0\u2013\u00a0a randomised feasibility study of selective bladder preservation versus radical cystectomy","volume":"120","author":"Huddart","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.canrad.2019.06.005_bib0470","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity score analysis of radical cystectomy vs bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0475","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.eururo.2017.03.038","article-title":"Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder","volume":"72","author":"Seisen","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0480","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.critrevonc.2015.04.006","article-title":"Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: a systematic review of clinical trials","volume":"95","author":"Arcangeli","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0485","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.urolonc.2017.10.002","article-title":"A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle invasive bladder cancer","volume":"36","author":"Fahmy","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0490","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.1996.14.11.2901","article-title":"Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Coppin","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0495","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2019.06.005_bib0500","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ijrobp.2016.11.040","article-title":"Tolerability of concurrent chemoradiation therapy with gemcitabine (gemx), with and without prior neoadjuvant chemotherapy, in muscle invasive bladder cancer","volume":"97","author":"Thompson","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2019.06.005_bib0505","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.18.00537","article-title":"Bladder preservation with twice-a-day radiation plus fluorouracil\/cisplatin or once daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG\/RTOG 0712-A randomized phase II trial","volume":"37","author":"Coen","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0510","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(13)70255-9","volume":"14","author":"Mitin","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0515","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.euo.2018.09.013","article-title":"combining immunotherapy with radiotherapy for the treatment of genitourinary malignancies","volume":"2","author":"Solanki","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0520","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ijrobp.2018.04.070","article-title":"Dose-limiting urinary toxicity with pembrolizumab combined with weekly hypofractionated radiation therapy in bladder cancer","volume":"101","author":"Tree","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2019.06.005_bib0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.meddos.2016.09.003","article-title":"Bladder radiotherapy treatment: a retrospective comparison of 3-dimensional conformal radiotherapy, intensity-modulated radiation therapy, and volumetric-modulated arc therapy plans","volume":"42","author":"Pasciuti","year":"2017","journal-title":"Med Dosim"},{"key":"10.1016\/j.canrad.2019.06.005_bib0530","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13014-016-0618-6","article-title":"Clinical results of conformal versus intensity-modulated radiotherapy using a focal simultaneous boost for muscle-invasive bladder cancer in elderly or medically unfit patients","volume":"11","author":"Lutkenhaus","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0535","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.21873\/anticanres.12793","article-title":"Partial bladder boost using lipiodol marking during image-guided radiotherapy for bladder cancer","volume":"38","author":"Nakamura","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.canrad.2019.06.005_bib0540","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.canrad.2017.09.013","article-title":"Trimodalities for bladder cancer in elderly: transurethral resection, hypofractionated radiotherapy and gemcitabine","volume":"22","author":"Mohamed","year":"2018","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2019.06.005_bib0545","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10147-016-1068-8","article-title":"Biomarkers for precision medicine in bladder cancer","volume":"22","author":"Kojima","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.06.005_bib0275","doi-asserted-by":"crossref","first-page":"e683","DOI":"10.1016\/S1470-2045(18)30693-4","article-title":"Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer","volume":"19","author":"Miyamoto","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321819302914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321819302914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:33:55Z","timestamp":1761136435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321819302914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":55,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1278321819302914"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2019.06.005","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pr\u00e9servation par chimioradioth\u00e9rapie des cancers de vessie","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2019.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}